Diversity management of patents in M&A - a case of Japanese pharmaceutical firms Online publication date: Thu, 31-Jul-2014
by Seiya Shimanuki; Tomoko Saiki
International Journal of Intellectual Property Management (IJIPM), Vol. 5, No. 3/4, 2012
Abstract: The purpose of this study is to propose an analysis of pharmaceutical effect areas of patent data as output of research and development (R&D) activities and as resources of the firm in mergers and acquisitions (M&A). We used two M&A cases of Japanese pharmaceutical firms of the partners with different technology relatedness. It is demonstrated that M&A had a negative effect on the R&D activities of the consolidated firm of technologically heterogeneous partners. The results also show that there are no increases in the proportion of patents with the most diversified effect areas in M&A of technologically heterogeneous partners and there is an increase in another M&A of technologically homogeneous partners. It is advisable that the partner firms cooperate to manage their patents in order to maintain patents in diversified areas rather than managing their patents more diversified as a whole, in order not to have a negative effect.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Intellectual Property Management (IJIPM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook